share_log

NovaBay Pharmaceuticals To Reconvene Special Meeting Of Stockholders To December 18, 2024; Initial Meeting Adjourned Due To Insufficient Votes To Reach The 50% Threshold Of Outstanding Common Shares Voting In Favor Of Proposal One And Two

NovaBay Pharmaceuticals To Reconvene Special Meeting Of Stockholders To December 18, 2024; Initial Meeting Adjourned Due To Insufficient Votes To Reach The 50% Threshold Of Outstanding Common Shares Voting In Favor Of Proposal One And Two

novabay製藥將於2024年12月18日重新召開股東特別大會;由於未能達到贊成提案一和提案二的優秀普通股選票的50%門檻,初始會議已延期。
Benzinga ·  2024/11/22 16:08

Initial meeting adjourned due to insufficient votes to reach the 50% threshold of outstanding common shares voting in favor of Proposal One and Proposal Two

初次會議因未能獲得足夠票數通過第一和第二提案的50%閾值而延期

Stockholders who have not voted are strongly encouraged to vote FOR Proposal One and Proposal Two

強烈鼓勵未投票的股東投票支持提案一和提案二

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that its Special Meeting of Stockholders held on November 22, 2024 has been adjourned until December 18, 2024 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold of favorable votes of all outstanding shares of common stock required to approve each proposal.

novabay pharmaceuticals公司(紐交所股票代碼:NBY)(「novabay」或「公司」)宣佈,其股東特別大會已於2024年11月22日召開,並將會議延期至2024年12月18日上午11:00太平洋時間,以爲股東提供額外時間投票支持提案一和提案二。兩項提案得到了大量股東已投票股份的支持,但尚未達到批准每項提案所需的所有未對投票的普通股的50%贊成票閾值。

  • Proposal One is a proposal to approve the sale of Avenova, representing substantially all of the assets of the Company (the "Asset Sale"), pursuant to the Asset Purchase Agreement, dated September 19, 2024, by and between the Company and PRN Physician Recommended Nutriceuticals, LLC.
    • Proposal Two is a proposal to approve the liquidation and dissolution of the Company, pursuant to the Plan of Complete Liquidation and Dissolution of the Company (the "Plan of Dissolution") which, if approved, would authorize the Company to liquidate and dissolve in accordance with the Plan of Dissolution, and pursuant to the discretion of the Board of Directors to proceed with the dissolution.
  • 提案一是批准出售Avenova資產(公司幾乎所有資產)的提案(「資產出售」),根據由公司和PRN Physician Recommended Nutriceuticals, LLC於2024年9月19日訂立的資產購買協議進行。
    • 提案二是批准公司清算和解散的提案,根據公司完全清算和解散計劃(「解散計劃」)進行,如果獲得批准,將授權公司根據解散計劃進行清算和解散,並由董事會自行決定是否繼續進行解散。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論